Table 1 Demographics and clinical features of patients

Age (mean ± SD)

52.84 ± 10.58

52.75 ± 10.56

53.04 ± 10.65

Medical insurance (%)

 URBMI

2868 (72.02)

2000 (71.74)

868 (72.70)

 UEBMI

1114 (27.98)

788 (28.26)

326 (27.30)

Marital (%)

 Married

3613 (90.73)

2518 (90.32)

1095 (91.71)

 Others

369 (9.27)

270 (9.68)

99 (8.29)

Ethnic (%)

 Han

3884 (97.54)

2715 (97.38)

1169 (97.91)

 Minority

98 (2.46)

73 (2.62)

25 (2.09)

Pathological (%)

 Squamous carcinoma

3468 (87.09)

2418 (86.73)

1050 (87.94)

 Adenocarcinoma

390 (9.79)

286 (10.26)

104 (8.71)

 Others

124 (3.11)

84 (3.01)

40 (3.35)

FIGO staging (%)

 I

1358 (34.10)

950 (34.07)

408 (34.17)

 II

1246 (31.29)

857 (30.74)

389 (32.58)

 III

1108 (27.83)

793 (28.44)

315 (26.38)

 IV

270 (6.78)

188 (6.74)

82 (6.87)

HPV (%)

 negative

1737 (43.62)

1213 (43.51)

524 (43.89)

 Positive

2245 (56.38)

1575 (56.49)

670 (56.11)

Surgery (%)

 NO

1961 (49.25)

1383 (49.61)

578 (48.41)

 YES

2021 (50.75)

1405 (50.39)

616 (51.59)

Radiotherapy (%)

 NO

2593 (65.12)

1800 (64.56)

793 (66.42)

 YES

1389 (34.88)

988 (35.44)

401 (33.58)

Chemotherapy (%)

 NO

2589 (65.02)

1794 (64.35)

795 (66.58)

 YES

1393 (34.98)

994 (35.65)

399 (33.42)

β2.microglobulin (%)

 ≤ 2.5

2785 (69.94)

1946 (69.80)

839 (70.27)

 > 2.5

1197 (30.06)

842 (30.20)

355 (29.73)

A/G ratio (%)

 ≤ 1.8

3636 (91.31)

2536 (90.96)

1100 (92.13)

 > 1.8

346 (8.69)

252 (9.04)

94 (7.87)

NLR (%)

 ≤ 4.5

3292 (82.67)

2322 (83.29)

970 (81.24)

 > 4.5

690 (17.33)

466 (16.71)

224 (18.76)

PLR (%)

 ≤ 216.52

3106 (78.00)

2160 (77.47)

946 (79.23)

 > 216.52

876 (22.00)

628 (22.53)

248 (20.77)